Zydus Lifesciences gains on getting USFDA`s final approval for Paliperidone Extended-Release Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Zydus Lifesciences is currently trading at Rs. 1062.75, up by 5.75 points or 0.54% from its previous closing of Rs. 1057.00 on the BSE.
The scrip opened at Rs. 1062.00 and has touched a high and low of Rs. 1064.15 and Rs. 1052.00 respectively. So far 67192 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023.
Last one week high and low of the scrip stood at Rs. 1070.70 and Rs. 1035.75 respectively. The current market cap of the company is Rs. 106957.64 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.17% and 6.85% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg (USRLD: Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg). Paliperidone extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia, acute treatment of schizoaffective disorder as monotherapy and acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants.
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad. The group now has 400 approvals and has so far filed over 465 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
